

CHF Solutions to Attend Southwest Nephrology Conference and Cardio Renal Metabolic Conference

October 3, 2018

EDEN PRAIRIE, Minn., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq: CHFS) today announced that the company will be an exhibitor at the 19th Annual Southwest Nephrology Conference and 6th Annual Cardio Renal Metabolic Conference to be held jointly on October 5-6, 2018 at the Pointe Hilton Tapatio Resort in Phoenix, Ariz. The company will be exhibiting at Booth #211.

"This conference is an important addition to our calendar as it addresses both a practitioner base and a region that are important components in our outreach strategy," said John Erb, chairman and CEO of CHF Solutions. "We look forward to connecting with potential prescribers and educating them on our alternative solution to fluid overload in heart failure patients when diuretics fail."

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow® system for Aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, our plans for the 19th Annual Southwest Nephrology Conference and 6th Annual Cardio Renal Metabolic Conference and our ability to connect with potential prescribers and educate them on our products. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:

Claudia Napal Drayton Chief Financial Officer CHF Solutions, Inc. 952-345-4205 ir@chf-solutions.com

-or-Bret Shapiro Managing Partner CORE IR 516-222-2560 brets@coreir.com www.coreir.com

MEDIA

Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@igapartners.com



Source: CHF Solutions, Inc.